Biopharmaceutical Principles of Injectable Dispersed Systems

Injectable Dispersed Systems: Formulation, Processing, and Performance

Volumn , Issue , 2005, Pages 39-76

  Oussoren, C ^a   Talsma, H ^a   Zuidema, J ^a   Kadir, F ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Postacademic Education for Pharmacists   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85051937836     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780849350610-6     Document Type: Chapter

References (110)

1. Gibaldi M. Biopharmaceutics and Clinical Pharmacokinetics. Philadelphia: Lea and Febiger, 1977.
2. Zuidema J, Pieters FAJM, Duchateau GSMJE. Release and absorption rate aspects of intramuscularly injected pharmaceuticals. Int J Pharm 1988; 47:1-12.
3. Zuidema J, Kadir F, Titulaer HAC, Oussoren C. Release and absorption rates of intramuscularly and subcutaneously injected pharmaceuticals (II). Int J Pharm 1994; 105:189-207.
4. Titulaer HAC, Eling WMC, Zuidema J. Pharmacokinetic and pharmacodynamic aspects of artelinic acid in rodents. J Pharm Pharmacol 1993; 45:830-835.
5. Groothuis DG, Werdler MEB, van Miert ASJPAM, van Duin CTM. Factors influencing the absorption of ampicillin administered intramuscularly in dwarf goats. Res Vet Sci 1980; 29:116-117.
6. Ballard BE. Biopharmaceutical considerations in subcutaneous and intramuscular drug administration. J Pharm Sci 1968; 57:357-378.
7. Raeder JC, Nilsen OG. Prolonged elimination of midazolam after i.m. administration. Acta Anaesthesiol Scand 1988; 32:464-466.
8. Raeder JC, Breivik H. Premedication with midazolam in outpatient anaesthesia. A comparison with morphinescopolamine and placebo. Acta Anaesthesiol Scand 1987; 31:509-514.
9. Tse FLS, Welling PG. Bioavailability of parenteral drugs. I. Intravenous and intramuscular doses. J Parent Drug Ass 1980; 34:409-421.
10. Kostenbauder HB, Rapp RP, McGroven JP et al. Bioavailability and single-dose pharmacokinetics of intramuscular phenytoin. Clin Pharmacol Ther 1976; 18:449-456.
11. Viswanathan CT, Booker HE, Welling PG. Bioavailability of oral and intramuscular phenobarbital. J Clin Pharmacol 1978; 18:100-105.
12. Cheng-Der Yu, Kent JS. Effect of propylene glycol on subcutaneous absorption of a benzidamole hydrochloride. J Pharm Sci 1982; 71:476-478.
13. Hung OR, Dyck B, Varvel JR, Shafer SL, Stansky DR. Intramuscular absorption kinetics of midazolam and diazepam in healthy volunteers. Clin Pharmacol Ther 1992; 51:130.
14. Kadir F, Zuidema J, Pijpers A, Melendez R, Vulto A, Verheijden JHM. Pharmacokinetics of intra-adiposely and intramuscularly injected carazolol in pigs. J Vet Pharmacol Ther 1990; 13:350-355.
15. Kadir F, Zuidema J, Pijpers A, Vulto A, Verheijden JHM. Drug lipophilicity and release pattern of some b-blocking agents after intra-adipose and intramuscular injection in pigs. Int J Pharm 1990; 64:171-180.
16. Charman WN, Stella VJ, eds. Lymphatic Transport of Drugs. Boca Raton, FL: CRC Press, 1992.
17. Titulaer HAC, Zuidema J, Kager PA, Wetsteyn JCFM, Lugt ChB, Merkus FWHM. The pharmacokinetics of artemisinin after oral, intramuscular and rectal administration to volunteers. J Pharm Pharmacol 1990; 42:810-813.
18. Al-Hindawi MK, James KC, Nicholls PJ. Influence of solvent on the availability of testosterone propionate from oily, intramuscular injections in rat. J Pharm Pharmacol 1986; 39:90-95.
19. Oussoren C, Storm G, Crommelin DJA, Senior JH. Liposomes for local sustained drug release. In: Senior JH, Radomsky ML, Sustained Release Injectable Products. Denver, Colorado: Interpharm Press, 1999:137-180.
20. Allen TM, Hansen CB, Guo LSS. Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. BBA 1993; 1150(1):9-16.
21. Patel HM. Fate of liposomes in the lymphatics. In: Gregoriadis G, ed. Liposomes as Drug Carriers. John Wiley and Sons Ltd. 1988: 51-61.
22. Tümer A, Kirby C, Senior J, Gregoriadis G. Fate of cholesterol-rich liposomes after subcutaneous injection into rats. BBA 1983; 760:119-125.
23. Oussoren C, Zuidema J, Crommelin DJAC, Storm G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid composition and lipid dose. Biochem Biophys Acta 1997; 1328:261-272.
24. Kim S, Howell SB. Multivesicular liposomes containing cytarabine entrapped in the presence of hydrochloric acid for intracavitary chemotherapy. Cancer Treatment Rep 1987; 71(7-8):705-711.
25. Kim T, Kim J, Kim S. Extended-release formulation of morphine for subcutaneous administration. Cancer Chemother Pharmacol 1993; 333:187-190.
26. Stevenson RW, Patel HM, Parson JA, Ryman BE. Prolonged hypoglycemic effect in diabetic dogs due to subcutaneous administration of insulin in liposomes. Diabetes 1982; 31:506-511.
27. Eppstein DA, van der Pas MA, Gloff CA, Soike KF. Liposomal interferon-b: sustained release treatment of simian varicella virus infection in monkeys. J Infect Dis 1989; 159:616-620.
28. Oussoren C, Storm G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. III. Influence of surface modification with poly(ethyleneglycol). Pharm Res 1997; 14:1479-1484.
29. Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997; 28:5-24.
30. Hennink WE, Talsma H, Borchert CJH, De Smedt SC, Demeester J. Controlled release of proteins from dextran hydrogels. J Control Release 1996; 39:47-55.
31. Hunt CA. Liposome disposition in vivo. V. Liposome stability in plasma and implications for drug carrier function. Biochim Biophys Acta 1982; 719:450-463.
32. Allen TM, Cleland LG. Serum induced leakage of liposome contents. Biochim Biophys Acta 1980; 597:418-426.
33. Damen J, Dijkstra J, Regts J, Scherphof G. Effect of lipoprotein-free plasma on the interaction of human plasma high density lipoprotein with egg yolk phosphatidylcholine liposomes. Biochim Biophys Acta 1980; 620:90-99.
34. Hernandez-Caselles T, Villalain J, Gomez-Fernandez JC. Influence of liposome charge and composition on their interaction with human blood serum proteins. Mol Cell Biochem 1993; 120:119-126.
35. Finkelstein MC, Weissmann G. Enzyme replacement via liposomes. Variations in lipid composition determine liposomal integrity in biological fluids. Biochim Biophys Acta 1979; 587:202-216.
36. Guo LSS, Hamilton RL, Goerke J, Weinstein JN, Havel RJ. Interaction of unilamellar liposomes with serum lipoproteins and apolipoproteins. J Lip Res 1980; 21:993-1003.
37. Mercadal M, Domingo JC, Bermudez M, Mora M, Africa de Madariaga M. N-palmitoylphosphatidylethanolamine stabilizes liposomes in the presence of human serum: effect of lipidic composition and system characterization. Biochim Biophys Acta 1995; 1235:281-288.
38. Schreier H, Levy M, Mihalko P. Sustained release of liposome-encapsulated gentamicin and the fate of phospholipid following intramuscular injection in mice. J Control Release 1987; 5:187-192.
39. Koppenhagen FJ. Liposomes as Delivery Systems for Recombinant Interleukin-2 in Anticancer Immunotherapy. PhD Thesis, Utrecht University, Utrecht, 1997.
40. Kim CK, Han JH. Lymphatic delivery and pharmacokinetics of methotrexate after intramuscular injection of differently charged liposome-entrapped methotrexate to rats. J Microencapsul 1995; 12(4):437-446.
41. Stevenson RW, Patel HM, Parson JA, Ryman BE. Prolonged hypoglycemic effect in diabetic dogs due to subcutaneous administration of insulin in liposomes. Diabetes 1982; 31:506-511.
42. Kim MM, Lee SH, Lee MG, Hwang SJ, Kim CK. Pharmacokinetics of methotrexate after intravenous and intramuscular injection of methotrexate-bearing positively charged liposomes to rats. Biopharm Drug Dispos 1995; 16:279-293.
43. Jeong YN, Lee SH, Lee MG, Hwang SJ, Kim CK. Pharmacokinetics of methotrexate after intravenous and intramuscular injection of methotrexate-bearing negatively charged liposomes to rats. Int J Pharm 1994; 102:35-46.
44. Schriftman H, Kondritzer AA. Absorption of atropine from muscle. Am J Physiol 1957; 191:591-594.
45. Warner GF, Dobson EL, Pace N, Johnston ME, Finney CR. Studies of peripheral bloodflow: the effect of injection volume on the intramuscular radiosodium clearance rate. Circulation 1953; 8:732-734.
46. Sund RB, Schou J. The determination of absorption rates from rat muscles: an experimental approach to kinetic descriptions. Acta Pharmacol Toxicol 1964; 21:313-325.
47. Hirano K, Ichihashi T, Yamada H. Studies on the absorption of practically water-insoluble drugs following injection. II:Intramuscular absorption from aqueous suspensions in rats. Chem Pharm Bull 1981; 29:817-827.
48. Hirano K, Yamada H. Studies on the absorption of practically water-insoluble drugs following injection. VI: Subcutaneous absorption from aqueous suspensions in rats. J Pharm Sci 1982; 71:500-505.
49. Hirano K, Yamada H. Studies on the absorption of practically water-insoluble drugs following injection. VII: Plasma concentration after different subcutaneous doses of a drug in aqueous suspensions in rats. J Pharm Sci 1983; 72:602-607.
50. Hirano K, Yamada H. Studies on the absorption of practically water-insoluble drugs following injection. VIII: Comparison of subcutaneous absorption from aqueous suspensions in mouse, rat and rabbit. J Pharm Sci 1983; 72:609-612.
51. Ober SS, Vincent HC, Simon DE, Frederick KJ. A rheological study of procain penicillin G depot preparations. J Am Pharm Assoc 1958; 47:667-676.
52. Kadir F, Seijsener CBJ, Zuidema J. Influence of the injection volume on the release pattern of intramuscularly administered propranolol to rats. Int J Pharm 1992; 81:193-198.
53. Tanaka T, Kobayashi H, Oumura K, Muranashi S, Sezaki H. Intramuscular absorption of drugs from oily solutions. Chem Pharm Bull 1974; 22:1275-1284.
54. Hirano K, Ichihashi T, Yamada H. Studies on the absorption of practically water-insoluble drugs following injection. II:Intramuscular absorption from aqueous suspensions in rats. Chem Pharm Bull 1981; 29:817-827.
55. Hirano K, Yamada H. Studies on the absorption of practically water-insoluble drugs following injection. VI: Subcutaneous absorption from aqueous suspensions in rats. J Pharm Sci 1982; 71:500-505.
56. Hirano K, Yamada H. Studies on the absorption of practically water-insoluble drugs following injection. VII: Plasma concentration after different subcutaneous doses of a drug in aqueous suspensions in rats. J Pharm Sci 1983; 72:602-607.
57. Hirano K, Yamada H. Studies on the absorption of practically water-insoluble drugs following injection. VIII: Comparison of subcutaneous absorption from aqueous suspensions in mouse, rat and rabbit. J Pharm Sci 1983; 72:609-612.
58. Kadir F, Eling WMC, Crommelin DJA, Zuidema J. Influence on release kinetics of liposomal chloroquine after s.c. and i.m. injection into mice. J Control Release 1991; 17:277-284.
59. Kadir F, Eling WMC, Crommelin DJA, Zuidema J. Kinetics and prophylactic efficacy of increasing dosages of liposome encapsulated chloroquine after intramuscular injection in mice. J Control Release 1992; 20:47-54.
60. Kadir F, Eling WMC, Crommeling DJA, Zuidema J. Influence of injection volume on the release kinetics of liposomal chloroquine administered intramuscularly or subcutaneously to mice. J Control Release 1991; 17:277-284.
61. Cockshott WP, Thompson GT, Howlett KL, Seely ET. Intramuscular or intralipomatous injections? N Engl J Med 1982; 307:356-358.
62. Vukovich RA, Brannick LJ, Sugerman AA, Neiss ES. Sex differences in the intramuscular absorption and bioavailability of cephradine. Clin Pharmacol Ther 1976; 18:215-220.
63. Dundee JW, Gamble JAS, Assaf RAE. Plasma diazepam levels following intramuscular injection by nurses and doctors. Lancet 1974; II:1461.
64. Shill M, Baynes RD, Miller SD. Fatal rabies encephalitis despite appropriate post-exposure prophylaxis. N Engl J Med 1987; 316:1257-1258.
65. Modderman ESM, Merkus FWHM, Zuidema J, Hilbers HW, Warndorff T. Sex differences in the absorption of dapsone after intramuscular injection. Int J Lepr 1983; 51:359-365.
66. Pieters FAJM, Zuidema J, Merkus FWHM. Sustained release properties of an intraadiposely administered dapsone depot injection. Int J Lepr 1986; 54:383-388.
67. Pieters FAJM, Woonink F, Zuidema J. A field trial among leprosy patients with depot injections of dapsone and monoacetyldapsone. Int J Leprosy 1988; 56:10-20.
68. Oussoren C, Zuidema J, Crommelin DJA, Storm G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. I Influence of anatomical site of injection. J Liposome Res 1997; 7:85-99.
69. Allen TM, Smuckler EA. Liver pathology accompanying chronic liposome administration in mouse. Res Commun Chem Pathol Pharmacol 1985; 50(2):281-290.
70. Allen TM, Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochem Biophys Acta 1991; 1068:133-141.
71. Allen TM. Toxicity of drug carriers to the mononuclear phagocyte system. Adv Drug Deliv Rev 1988; 2:55-67.
72. Harashima H, Kume Y, Yamane C, Kiwada H. Kinetic modeling of liposome degradation in blood circulation. Biopharm Drug Dispos 1993; 14:265-270.
73. Devine DV, Wong K, Serrano K, Chonn A, Cullis PR. Liposomecomplement interactions in rat serum: implications for liposome survival studies. Biochim Bhiophys Acta 1994; 1191:43-51.
74. Patel HM. Serum opsonins and liposomes: their interaction and opsonophagocytosis. Crit Rev Ther Drug Carrier Syst 1992; 9:39-90.
75. Juliano RL. Factors controlling the kinetics and tissue distribution of liposomes, microspheres, and emulsions. Adv Drug Deliv Rev 1988; 2:31-54.
76. Moghimi SM, Patel HM. Serum mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system- the concept of tissue specificity. Adv Drug Deliv Rev 1998; 32:45-60.
77. Harashima H, Ohnishi Y, Kiwada H. In vivo evaluation of the effect of the size and opsonisation on the hepatic extraction of liposomes in rats: an application of Oldendorf method. Biopharm Drug Dispos 1992; 13:549-553.
78. Moghimi SM, Patel HM. Calcium as a possible modulator of Kupffer cell phagocytic function by regulation liver-specific opsonic activity. Biochim Biophys Acta 1990; 1028:304-308.
79. Senior JH. Fate and behaviour of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst 1987; 3(2):123-193.
80. Gabizon A, Papahadjopoulos D. The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim Biophys Acta 1992; 1103:94-100.
81. Storm G, Belliot SO, Daeman T, Lasic DD. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 1995; 17:31-48.
82. Klibanov AL, Huang L. Long-circulating liposomes: development and perspectives. J Liposome Res 1992; 2(3):321-334.
83. Allen TA, Hansen CB, Lopes de Menezes DE. Pharmacokinetics of long-circulating liposomes. Adv Drug Deliv Rev 1995; 16:267-284.
84. Woodle M, Lasic DD. Sterically stabilized liposomes. Biochim Biophys Acta 1992; 1113:171-199.
85. Bakker-Woudenberg IAJM, Storm G, Woodle MC. Liposomes in the treatment of infections. J Drug Targeting 1994; 2:363-371.
86. Torchilin VP, Trubetskoy VS. Which polymers can make nanoparticulate drug carriers long-circulating? Adv Drug Deliv Rev 1995; 16:141-155.
87. Gabizon A, Shiota R, Papahadjopoulos D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulating times. J Natl Cancer Inst 1989; 81(19):1484-1878.
88. Bakker-Woudenberg IAJM, LokerseAF, tenKateMT, StormG. Enhanced localization of liposomes with prolonged circulating time in infected lung tissue. Biochim Biophys Acta 1992; 1138:318-326.
89. Bakker-Woudenberg IAJM, Lokerse AF, ten Kate MT, Mouton JW, Woodle MC, Storm G. Liposomes with prolonged blood circulation and selective localization in Klebsiellapneumoniae- infected lung tissue. J Infect Dis 1993; 168:164-171.
90. Peeters PAM, Storm G, Crommelin DJA. Immunoliposomes in vivo: state of the art. Adv Drug Deliv Rev 1987; 1:249-266.
91. Nässander UK, Steerenberg PA, Poppe H, Storm G, Poels LG, de Jong WH, Crommelin DJA. In vivo targeting of OV-TL 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice. Cancer Res 1992; 52:646-653.
92. Vingerhoeds MH, Storm G, Crommelin DJA. Immunoliposomes in vivo. Immunomethods 1994; 4:259-272.
93. Blume G, Cevc G, Crommelin DJA, Bakker-Woudenberg IAJM, Kluft C, Storm G. Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of polymeric chains combines effective target binding with long circulation times. BBA 1993; 1149:180-184.
94. Allen TM. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. TIPS 1994; 15:215-220.
95. Allen TA, Agrawal AK, Ahmad I, Hansen CB, Zalipsky S. Anti-body mediated targeting of long-circulating (stealth) liposomes. J Liposome Res 1994; 4:1-25.
96. Bendas G, Krause A, Bakowsky U, Vogel J, Rothe U. Targetability of movel immunoliposomes prepared by a new antibody conjugation technique. Int J Pharm 1999; 181:79-93.
97. Maruyama K. PEG-immunoliposomes. Biosci Rep 2002; 22:252-266.
98. Koning G, Morselt HWM, Gorter A, Allen TM, Zalipsky S, Kamps JAAM, Scherphof GL. Pharmacokinetics of differently designed immunoliposome formulation in rats with or without hepatic colon cancer metastases. Pharm Res 2001; 18:1291-1298.
99. Bakker-Woudenberg IAJM, Lokerse AF, ten Kate MT, Mouton JW, Woodle MC, Storm G. Liposomes with prolonged blood circulation and selective localization in Klebsiellapneumoniae- infected lung tissue. J Infect Dis 1993; 168:164-171.
100. Park JW, Kirpiotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC. Tumor targeting using anti-her2 immunoliposomes. Journal of controlled release 2001; 74:95-113.
101. Lopes de Menezes DE, Pilarsky LM, Belch AR, Allen TM. Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo. BBA Biomembranes 2000; 1466:205-220.
102. Gabizon A, Goren D, Horowitz AT, Tzemach D, Lossos A, Siegal T. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumorbearing animals. Adv Drug Deliv Rev 1997; 24:337-344.
103. Forssen EA, Tökes ZA. Attenuation of dermal toxicity of doxorubicin by liposome encapsulation. Cancer Treatment Rep 1983; 67(5):481-484.
104. Axelsson B. Liposomes as carriers for anti-inflammatory agents. Adv Drug Deliv Rev 1989; 3:391-404.
105. Litterst CL, Sieber SM, Copley M, Parker RJ. Toxicity of free and liposome-encapsulated adriamycin following large volume, short-term intraperitoneal exposure in the rat. Toxicol Appl Pharmacol 1982; 64:517-528.
106. Kadir F, Oussoren C, Crommelin DJA. Liposomal formulations to reduce irritation of intramuscularly and subcutaneously administered drugs. In: Gupta PK, Brazeau GA, eds. Injectable Drug Development. Techniques to Reduce Pain and Irritation. Denver, Colorado: Interpharm Press, 1999:337-354.
107. Svendsen F, Rasmussen F, Nielsen P, Steiness E. The loss of creatine phosphokinase (CK) from intramuscular injection sites in rabbits. A predictive tool for local toxicity. Acta Pharmacol Toxicol 1979; 44:324-328.
108. KadirF, ElingWMC, AbrahamsD, Zuidema J, CrommelinDJA. Tissue reaction after intramuscular injection of liposomes in mice. Int J Clin Pharmacol Ther Toxicol 1992; 30:374-382.
109. Al-Suwayeh AA, Tebbett IR, Wielbo D, Brazeau GA. In vitro- in vivo myotoxicity of intramuscular liposomal formulations. Pharm Res 1996; 13(9):1384-1388.
110. Oussoren C, ElingWMC, CrommelinDJA, StormG, ZuidemaJ. The influence of the route of administration and liposome composition on the potential of liposomes to protect tissue against local toxicity of two antitumor drugs. Biochem Biophys Acta 1998; 1369:159-172.